Kenya AIDS NGOs Consortium

Email

aragi@kanco.org

Phone

T: +254722203344

Web

http://kanco.org

Address

69866, Nairobi, Kenya 00400
About Kenya AIDS NGOs Consortium

The Kenya AIDS NGOs Consortium (KANCO) is a national membership network of non-profit, civil society, and faith-based organisations involved or having interest in HIV/AIDs activities within Kenya. KANCO was established in 1990. KANCO’s vision is a Kenyan society free of HIV & AIDS and TB while its mission is to provide leadership, promote collaboration and enhance capacity among Civil Society Organisations (CSOs) and other stakeholders to respond to HIV & AIDS and TB at the community level. The goal of the consortium is to provide leadership among CSOs in contribution towards realization of universal access targets in Kenya which is to be achieved through three overarching strategic objectives.

Some of their hepatitis related activities are:

  1. Community-Led Hepatitis Advocacy
    KANCO has been instrumental in mobilizing community-based efforts to raise awareness about hepatitis. It has supported the formation of the Hepatitis Advocacy Group, which focuses on amplifying voices to promote hepatitis elimination in Kenya.
    2. Integration of Hepatitis Services into Harm Reduction Programs
    Recognizing the high prevalence of Hepatitis C among people who inject drugs (PWID), KANCO has advocated for the integration of hepatitis services into existing harm reduction programs. This approach aims to provide comprehensive care, including screening and treatment, to vulnerable populations.
    3. Policy Advocacy and Stakeholder Engagement
    KANCO engage in policy advocacy to influence national health strategies related to hepatitis. KANCO has worked collaboratively with stakeholders to develop and implement policies that support hepatitis prevention and control efforts across the country.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close